Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: BuySellSignals Research
$5.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glenmark Pharmaceuticals Ltd's Glenmark Generics Limited Confirms Patent Challenge For VIPMAT


Friday, 12 Jul 2013 06:45am EDT 

Glenmark Generics Limited, the United States subsidiary of Glenmark Pharmaceuticals Ltd announced that it has filed Abbreviated New Drug Applications (ANDAs) for Lacosamide Tablets, and Oral Solution with the U.S. Food and Drug Administration (FDA) with a Paragraph IV Certification for the Orange-Book listed patent. Glenmark’s ANDA products are generic versions of VIMPAT, which are indicated for an adjunctive therapy in the treatment for partial-onset seizures in adults with epilepsy. UCB, INC., UCS Pharma GmbH, Research Corporation Technologies, Inc. and Harris FRC Corporation filed suit against Glenmark Generics Limited and Glenmark Generics Inc. on July 10, 2013, in the United States District Court for the District of Delaware, seeking to prevent Glenmark from commercializing its ANDA product prior to the expiration of U.S. Patent No.RE 38,551. This lawsuit was filed under the provisions of the Hatch-Waxman Act. If Glenmark is successful in its challenge of the patent, it will garner 180-day exclusivity for its products. 

Company Quote

574.1
3.15 +0.55%
22 Jul 2014